Therefore, failure to build an ER stress response in the liver may be a causal factor in obesity-related diabetes and nonalcoholic steatohepatitis, for which Sdf2l1 could serve as a therapeutic target and sensitive biomarker. This evidence concerns the gene SDF2L1 and metabolic dysfunction-associated steatohepatitis.